By 
Vaccine maker’s quarterly profit falls on charges tied to expired doses, changes to purchase agreements
Moderna is the latest drugmaker to post quarterly sales gains due to continued demand for its Covid-19 products.Photo: Rogelio V. Solis/Associated Press
Moderna sales rose 9% in the second quarter as demand for its Covid-19 vaccine remained strong.
The Cambridge, Mass.-based biotechnology company’s revenue came in at $4.75 billion in the period ended June 30, topping Wall Street analyst expectations, driven almost entirely by sales of its messenger RNA-based vaccine, branded as Spikevax.
Comments